How many insider trades does FilingIQ track for TRVI?

FilingIQ tracks 192 Form 4 insider transactions for TRVI (Trevi Therapeutics, Inc.), covering filings from May 9, 2019 onwards. 5 of those were filed in the last 90 days.

Are TRVI insiders net buyers or net sellers?

Across the full Form 4 history for TRVI, 60 transactions (31%) were open-market purchases and 44 (23%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does TRVI insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is TRVI in?

Trevi Therapeutics, Inc. (TRVI) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.36B.

TRVI insider trading

NasdaqGM Healthcare

Trevi Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

192

Last 90 days

Buys / sells

31% / 23%

Market cap

$1.36B

About Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis. Trevi Therapeutics, Inc. has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Company website: www.trevitherapeutics.com

TRVI insider activity at a glance

FilingIQ has scored 192 insider transactions for TRVI since May 9, 2019. The most recent filing in our index is dated Feb 19, 2026.

Across the full history, 60 open-market purchases and 44 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on TRVI insider trades is 53.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live TRVI trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding TRVI

Siren, L.L.C.

$18.01M · 1.0% of AUM

Frazier Life Sciences Management, L.P.

$12.86M · 0.8% of AUM

Frequently asked

How many insider trades does FilingIQ track for TRVI?: FilingIQ tracks 192 Form 4 insider transactions for TRVI (Trevi Therapeutics, Inc.), covering filings from May 9, 2019 onwards. 5 of those were filed in the last 90 days.
Are TRVI insiders net buyers or net sellers?: Across the full Form 4 history for TRVI, 60 transactions (31%) were open-market purchases and 44 (23%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does TRVI insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is TRVI in?: Trevi Therapeutics, Inc. (TRVI) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.36B.

Methodology & sources

Every TRVI insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.